Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001

Clinical Infectious Diseases

Volumn 36, Issue 4, 2003, Pages 429-439

  Fridkin, Scott K ^a   Hageman, Jeff ^a   McDougal, Linda K ^a   Mohammed, Jasmine ^a   Jarvis, William R ^a   Perl, Trish M ^b   Tenover, Fred C ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BACTERIAL DNA; CEFAZOLIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; NAFCILLIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PERITONITIS; BACTERIUM ISOLATE; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; FEMALE; HOSPITALIZATION; HUMAN; LIVER ABSCESS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; SPONDYLITIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; CASE-CONTROL STUDIES; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; UNITED STATES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0037442366     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/346207     Document Type: Article

References (27)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32.
2. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-June 2001. Am J Infect Control 2001; 29:404-21.
3. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999; 48:707-10.
4. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593-8.
5. Rotun SS, McMath V, Schoonmaker DJ, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999; 5:147-9.
6. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340:493-501.
7. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-46.
8. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48:1165-7.
9. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogenously resistant to vancomycin. Lancet 1997; 350:1670-3.
10. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. NCCLS document M7-A5. Wayne, PA: NCCLS, 2000.
11. Kloos WE, Banerman TL. Staphylococcus and Micrococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 7th ed. Washington, DC: American Society for Microbiology Press, 1999:264-82.
12. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing: approved standard. NCCLS document M100-S9. Wayne, PA: NCCLS, 1999.
13. Hubert SK, Mohammed JM, Fridkin SK, Gaynes RP, McGowan JE Jr, Tenover FC. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey. J Clin Microbiol 1999; 37:3590-3.
14. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7:1-9.
15. Tenover FC, Arbeit RD, Goering RV. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. Molecular Typing Working Group of the Society for Healthcare Epidemiology of America. J Clin Microbiol 1995; 33:2233-9.
16. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factor for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32:1055-61.
17. Anderson D, Naimi TS, O'Boyle C, et al. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia [abstract 13]. Clin Infect Dis 2001; 33:1090.
18. Hageman JC, Pegues DA, Jepson C, et al. Vancomycin-intermediate Staphylococcus aureus in a home health patient. Emerg Infect Dis 2001; 7:877-9.
19. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337:441-6.
20. Deikema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(Suppl 2):S114-32.
21. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340:517-23.
22. Howe RA, Wooton M, Bennet PM, MacGowan AP, Walsh TR. Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility. J Clin Microbiol 1999; 37:3068-71.
23. Sieradzki K, Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181:7566-70.
24. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999; 43:1747-53.
25. Boyle-Vavra S, Berke SK, Lee JC, Daum RS. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2000; 44:272-7.
26. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32:108-15.
27. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.